RaST consisted of zirconium-89 (89Zr)-labeled daratumumab to target MM cells and continuously activate orthogonally delivered titanium dioxide-transferrin-titanocene (TiO2-Tf-TC) nanoparticles for sustained cytotoxic ROS production. The gene discussed is TF; the disease is Miyoshi myopathy.